vs
Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and LCNB CORP (LCNB). Click either name above to swap in a different company.
GYRE THERAPEUTICS, INC. is the larger business by last-quarter revenue ($37.2M vs $23.9M, roughly 1.6× LCNB CORP). LCNB CORP runs the higher net margin — 23.7% vs -3.7%, a 27.4% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs 5.1%). LCNB CORP produced more free cash flow last quarter ($33.4M vs $-5.8M). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs 15.7%).
GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.
LCNB Corp is a United States-based financial holding company that operates through its national bank subsidiary, providing a full suite of retail and commercial banking products and services including deposit accounts, various loan products, wealth management, and insurance solutions primarily to individual consumers, small and medium-sized enterprises and local community organizations across regional markets in Ohio.
GYRE vs LCNB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $37.2M | $23.9M |
| Net Profit | $-1.4M | $5.7M |
| Gross Margin | 95.3% | — |
| Operating Margin | 0.3% | 29.2% |
| Net Margin | -3.7% | 23.7% |
| Revenue YoY | 33.4% | 5.1% |
| Net Profit YoY | -340.1% | -7.6% |
| EPS (diluted) | $-0.01 | $0.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $37.2M | $23.9M | ||
| Q3 25 | $30.6M | $23.8M | ||
| Q2 25 | $26.8M | $22.8M | ||
| Q1 25 | $22.1M | $21.5M | ||
| Q4 24 | $27.9M | $22.7M | ||
| Q3 24 | $25.5M | $21.4M | ||
| Q2 24 | $25.2M | $19.3M | ||
| Q1 24 | $27.2M | $17.8M |
| Q4 25 | $-1.4M | $5.7M | ||
| Q3 25 | $5.9M | $6.9M | ||
| Q2 25 | $1.6M | $5.9M | ||
| Q1 25 | $3.7M | $4.6M | ||
| Q4 24 | $569.0K | $6.1M | ||
| Q3 24 | $2.9M | $4.5M | ||
| Q2 24 | $4.5M | $925.0K | ||
| Q1 24 | $9.9M | $1.9M |
| Q4 25 | 95.3% | — | ||
| Q3 25 | 94.7% | — | ||
| Q2 25 | 95.7% | — | ||
| Q1 25 | 95.9% | — | ||
| Q4 24 | 95.8% | — | ||
| Q3 24 | 96.2% | — | ||
| Q2 24 | 96.9% | — | ||
| Q1 24 | 96.4% | — |
| Q4 25 | 0.3% | 29.2% | ||
| Q3 25 | 22.7% | 35.6% | ||
| Q2 25 | 8.1% | 31.6% | ||
| Q1 25 | 10.3% | 25.6% | ||
| Q4 24 | 2.4% | 32.9% | ||
| Q3 24 | 16.6% | 24.9% | ||
| Q2 24 | 12.7% | 4.9% | ||
| Q1 24 | 29.7% | 12.5% |
| Q4 25 | -3.7% | 23.7% | ||
| Q3 25 | 19.4% | 29.1% | ||
| Q2 25 | 5.9% | 26.0% | ||
| Q1 25 | 16.9% | 21.4% | ||
| Q4 24 | 2.0% | 27.0% | ||
| Q3 24 | 11.2% | 21.2% | ||
| Q2 24 | 18.0% | 4.8% | ||
| Q1 24 | 36.6% | 10.7% |
| Q4 25 | $-0.01 | $0.40 | ||
| Q3 25 | $0.03 | $0.49 | ||
| Q2 25 | $0.00 | $0.41 | ||
| Q1 25 | $0.00 | $0.33 | ||
| Q4 24 | $0.00 | $0.44 | ||
| Q3 24 | $0.01 | $0.31 | ||
| Q2 24 | $0.01 | $0.07 | ||
| Q1 24 | $0.03 | $0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $52.4M | $21.6M |
| Total DebtLower is stronger | — | $104.4M |
| Stockholders' EquityBook value | $106.0M | $273.9M |
| Total Assets | $166.1M | $2.2B |
| Debt / EquityLower = less leverage | — | 0.38× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $52.4M | $21.6M | ||
| Q3 25 | $60.0M | $35.9M | ||
| Q2 25 | $54.4M | $49.8M | ||
| Q1 25 | $29.9M | $37.7M | ||
| Q4 24 | $26.7M | $35.7M | ||
| Q3 24 | $25.1M | $39.4M | ||
| Q2 24 | $25.1M | $34.9M | ||
| Q1 24 | $37.4M | $33.0M |
| Q4 25 | — | $104.4M | ||
| Q3 25 | — | $104.7M | ||
| Q2 25 | — | $105.0M | ||
| Q1 25 | — | $104.6M | ||
| Q4 24 | — | $155.2M | ||
| Q3 24 | — | $155.7M | ||
| Q2 24 | — | $162.2M | ||
| Q1 24 | — | $162.6M |
| Q4 25 | $106.0M | $273.9M | ||
| Q3 25 | $101.9M | $269.9M | ||
| Q2 25 | $92.0M | $263.5M | ||
| Q1 25 | $68.1M | $258.7M | ||
| Q4 24 | $63.3M | $253.0M | ||
| Q3 24 | $63.2M | $253.2M | ||
| Q2 24 | $60.4M | $245.2M | ||
| Q1 24 | $56.6M | $233.7M |
| Q4 25 | $166.1M | $2.2B | ||
| Q3 25 | $159.4M | $2.2B | ||
| Q2 25 | $152.6M | $2.3B | ||
| Q1 25 | $129.8M | $2.3B | ||
| Q4 24 | $125.4M | $2.3B | ||
| Q3 24 | $125.2M | $2.3B | ||
| Q2 24 | $120.9M | $2.4B | ||
| Q1 24 | $122.0M | $2.3B |
| Q4 25 | — | 0.38× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | 0.40× | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 0.61× | ||
| Q2 24 | — | 0.66× | ||
| Q1 24 | — | 0.70× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.6M | $34.4M |
| Free Cash FlowOCF − Capex | $-5.8M | $33.4M |
| FCF MarginFCF / Revenue | -15.5% | 140.2% |
| Capex IntensityCapex / Revenue | 0.4% | 4.0% |
| Cash ConversionOCF / Net Profit | — | 6.08× |
| TTM Free Cash FlowTrailing 4 quarters | $-180.0K | $54.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.6M | $34.4M | ||
| Q3 25 | $4.7M | $14.0M | ||
| Q2 25 | $2.1M | $5.5M | ||
| Q1 25 | $-129.0K | $2.2M | ||
| Q4 24 | $-2.8M | $93.2M | ||
| Q3 24 | $1.7M | $11.9M | ||
| Q2 24 | $-5.5M | $54.9M | ||
| Q1 24 | $2.9M | $-11.9M |
| Q4 25 | $-5.8M | $33.4M | ||
| Q3 25 | $4.0M | $13.7M | ||
| Q2 25 | $1.8M | $5.2M | ||
| Q1 25 | $-251.0K | $2.1M | ||
| Q4 24 | $-2.8M | $89.4M | ||
| Q3 24 | $1.0M | $10.5M | ||
| Q2 24 | $-6.9M | $53.8M | ||
| Q1 24 | $2.7M | $-12.8M |
| Q4 25 | -15.5% | 140.2% | ||
| Q3 25 | 13.1% | 57.4% | ||
| Q2 25 | 6.8% | 23.0% | ||
| Q1 25 | -1.1% | 10.0% | ||
| Q4 24 | -10.1% | 394.0% | ||
| Q3 24 | 4.1% | 49.0% | ||
| Q2 24 | -27.5% | 278.6% | ||
| Q1 24 | 9.8% | -71.8% |
| Q4 25 | 0.4% | 4.0% | ||
| Q3 25 | 2.2% | 1.3% | ||
| Q2 25 | 1.0% | 1.0% | ||
| Q1 25 | 0.6% | 0.3% | ||
| Q4 24 | 0.2% | 16.7% | ||
| Q3 24 | 2.7% | 6.7% | ||
| Q2 24 | 5.8% | 5.9% | ||
| Q1 24 | 0.9% | 4.8% |
| Q4 25 | — | 6.08× | ||
| Q3 25 | 0.79× | 2.02× | ||
| Q2 25 | 1.32× | 0.92× | ||
| Q1 25 | -0.03× | 0.48× | ||
| Q4 24 | -4.85× | 15.23× | ||
| Q3 24 | 0.60× | 2.63× | ||
| Q2 24 | -1.21× | 59.35× | ||
| Q1 24 | 0.29× | -6.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
